- Home
- ACNB vs AUTL Comparison
ACNB vs AUTL Comparison
Compare ACNB & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACNB
- AUTL
- Stock Information
- Founded
- ACNB 1857
- AUTL 2014
- Country
- ACNB United States
- AUTL United Kingdom
- Employees
- ACNB N/A
- AUTL N/A
- Industry
- ACNB Major Banks
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACNB Finance
- AUTL Health Care
- Exchange
- ACNB Nasdaq
- AUTL Nasdaq
- Market Cap
- ACNB 405.4M
- AUTL 360.6M
- IPO Year
- ACNB N/A
- AUTL 2018
- Fundamental
- Price
- ACNB $40.63
- AUTL $1.43
- Analyst Decision
- ACNB Strong Buy
- AUTL Strong Buy
- Analyst Count
- ACNB 4
- AUTL 5
- Target Price
- ACNB $50.00
- AUTL $9.32
- AVG Volume (30 Days)
- ACNB 45.3K
- AUTL 1.8M
- Earning Date
- ACNB 05-02-2025
- AUTL 05-13-2025
- Dividend Yield
- ACNB 3.14%
- AUTL N/A
- EPS Growth
- ACNB 0.54
- AUTL N/A
- EPS
- ACNB 3.73
- AUTL N/A
- Revenue
- ACNB $111,104,000.00
- AUTL $10,120,000.00
- Revenue This Year
- ACNB $35.65
- AUTL $277.74
- Revenue Next Year
- ACNB $7.15
- AUTL $221.89
- P/E Ratio
- ACNB $10.89
- AUTL N/A
- Revenue Growth
- ACNB 4.89
- AUTL 496.00
- 52 Week Low
- ACNB $30.24
- AUTL $1.11
- 52 Week High
- ACNB $50.72
- AUTL $5.25
- Technical
- Relative Strength Index (RSI)
- ACNB 52.53
- AUTL 45.37
- Support Level
- ACNB $37.78
- AUTL $1.32
- Resistance Level
- ACNB $41.67
- AUTL $1.45
- Average True Range (ATR)
- ACNB 1.73
- AUTL 0.16
- MACD
- ACNB 0.09
- AUTL 0.02
- Stochastic Oscillator
- ACNB 76.55
- AUTL 61.90
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.